ANGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Angion Biomedica does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.
The historical data trend for Angion Biomedica's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Angion Biomedica Annual Data | ||||||||||||||||
Trend | Dec12 | Dec13 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Angion Biomedica Quarterly Data | ||||||||||||||||||||
Jun13 | Dec13 | Mar14 | Jun14 | Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Angion Biomedica's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Angion Biomedica's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Angion Biomedica's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Angion Biomedica does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.
Angion Biomedica (NAS:ANGN) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Angion Biomedica's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jay Venkatesan | director, officer: See Remarks | C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111 |
Allen Nissenson | director | 601 HAWAII ST., EL SEGUNDO CA 90245 |
John F. Neylan | officer: See Remarks | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
Gregory S Curhan | officer: See Remarks | 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
Jennifer J Rhodes | officer: See Remarks | C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608 |
Itzhak Goldberg | officer: See Remarks | 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553 |
Victor F Ganzi | director | |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Karen J Wilson | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Eisa-abc Llc | 10 percent owner | C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-05-2022
By Stock market mentor Stock market mentor • 01-21-2023
By Stock market mentor Stock market mentor • 01-17-2023
By PRNewswire PRNewswire • 03-28-2023
By Business Wire Business Wire • 02-27-2023
By Stock market mentor Stock market mentor • 01-17-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By PRNewswire PRNewswire • 01-26-2023
By Business Wire Business Wire • 01-17-2023
By Tiesvg Tiesvg • 12-22-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.